Boston Scientific's Drive To Add To Core Strength Continues With BTG Buy

If the news that UK interventional medicine specialist BTG PLC, strong, independent and fiercely committed to immovable quality standards in terms of its own M&A programs, is to be acquired was unexpected by many, the identity of the buyer was less of a surprise: Boston Scientific Corp. proved on Nov. 20 that its appetite for major M&A in 2018 is not yet exhausted when it made a bid for BTG, valuing the company at £3.3 billion ($4.28 billion).

In Vivo has tracked BTG of late, charting its ability to precision-target commercial entities that fit its interventional oncology and vascular portfolio interests. In late summer, Boston Scientific chief medical officer, Ian Meredith M.D., Ph.D, told In Vivo about the "category leadership" aims that the Marlborough, Mass